Life Sciences, deals, Biotech
Idera and Merck Extend R&D Deal
Ryan McBride 11/20/08
Idera Pharmaceuticals (NASDAQ:IDRA), a Cambridge, MA-based developer of drugs that target a family of immune system receptors, reports it has inked a one-year extension to its research collaboration with New Jersey-based drug giant Merck. The two companies began the collaboration in December 2006 to investigate Idera’s drugs as treatments for cancer, infectious diseases, and Alzheimer’s.
Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.
